Veritone, Inc. VERI 深 滬
已收盤 08-29 16:00:00 美东时间
3.05
+0.180
+6.27%
華盛通- 最 高3.07
- 今 開2.90
- 成交量 335.44万股
- 最 低 2.71
- 昨 收 2.87
- 總市值 1.65亿
- 52周最高 5.635
- 市盈率 靜 --
- 換手率 6.21%
- 52周最低 1.22
- 委 比 -74.77%
- 總股本 5400.50万
- 歷史最高 74.92
- 量 比 0.86
- 振 幅 12.54%
- 歷史最低 1.22
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 回声星通信飙升70%，AT&T拟以230亿美元收购其频谱许可证；先科电子涨超15%
回声星通信飙升70%，AT&T拟以230亿美元收购其频谱许可证；CareCloud涨超15%，完成对Medsphere的收购；Q2净销售额创下纪录，先科电子涨超15%>>
08-27 15:48
12 Information Technology Stocks Moving In Tuesday's Intraday Session
Gainers Lightwave Logic (NASDAQ:LWLG) stock rose 26.5% to $3.17 during Tuesday...
08-27 01:06
Protagonist Plans Year-End FDA Filing for Rusfertide After Strong Phase 3 Results in Blood Disorder Therapy
Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") announced today that rusfertide, a potential first-in-class hepcidin-mimetic peptide, has been granted Breakthrough Therapy Designation by the U.S. Food and
08-25 19:09
李嘉诚旗下核心创新药企，市值「仅剩」200亿港元
原标题：李嘉诚旗下核心创新药企，市值「仅剩」200亿港元 创新药市场的爆发，源自BD交易的催化。 在这种背景下，康方生物、信达生物、荣昌生物、中国生物制药、三...
08-11 11:45
Arvinas And Pfizer Announce FDA Accepts New Drug Application For Vepdegestrant For Treatment Of ESR1m, ER+/HER2- Advanced Breast Cancer
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –– Vepdegestrant is the
08-09 04:06
李嘉诚旗下和黄医药，股价闪崩！公司囤积现金近百亿元，大幅减少在中国以外的研发投资
李嘉诚旗下和黄医药（00013.HK），股价突然崩了！ 8月8日早盘，和黄医药股价开盘就跳水，截至中午收盘跌超15%，总市值207.21亿港元。 ...
08-08 13:31
Veritone Sees Q3 Sales $28.000M-$30.000M vs $27.721M Est
Veritone (NASDAQ:VERI) sees Q3 sales of $28.000 million-$30.000 million vs $27.721 million analyst estimate.
08-08 04:58
Veritone Raises FY2025 Sales Guidance from $104.000M-$115.000M to $108.000M-$115.000M vs $105.710M Est
Veritone (NASDAQ:VERI) raises FY2025 sales outlook from $104.000 million-$115.000 million to $108.000 million-$115.000 million vs $105.710 million estimate.
08-08 04:57
Veritone Q2 Adj. EPS $(0.18), Inline, Sales $24.013M Beat $23.578M Estimate
Veritone (NASDAQ:VERI) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $24.013 million
08-08 04:57
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
